Although the immune system has evolved to protect the host, it also possesses the power to damage the host. Overactive immune responses that fail to differentiate between the self and the non-self can give rise to autoimmune disorders. This article seeks to provide current information on components of both the innate and adaptive immune systems and illustrate how they effect the development and pathogenesis of autoimmune disease, specifically that of type 1 diabetes (T1D). Understanding how the immune system is failing to regulate and control immune responses are vital in understanding how to control these autoimmune disorders.
Autoimmunity in T1D
T1D is an autoimmune disease in which pathogenic T cells specifically target the destruction of insulinproducing cells within the pancreas. Without the hormone insulin, the body is unable to maintain normal blood glucose levels. Therefore, individuals suffering from T1D must inject insulin multiple times daily to survive.
Genome-wide association studies in T1D have identified over 20 putative loci of statistical significance, but thus far, only linkage to human leukocyte antigen (HLA) seems incontestable (1) . The search for non-HLA susceptibility genes has received great attention in recent years, and a region on chromosome 16p13, identified as KIAA0350, appears to be as a novel locus associated with T1D (2) .
T1D is a complex polygenic disease (3) for which there is a small number of genes with large effects (i.e., HLA) and a large number of genes with small effects (1) . Risk of T1D progression is conferred by specific HLA DR/DQ alleles [e.g., DRB1*03-DQB1*0201 (DR3) or DRB1*04-DQB1*0302 (DR4)] (4, 5) . The genotype associated with the highest risk for T1D is the DR3/4-DQ8 (DQ8 is DQA1*0301, DQB1*0302) heterozygous genotype. In addition, HLA genotypes such as DQB1*0602 confer dominant protection from T1D in multiple populations. There is a different disease risk for each major histocompatibility complex (MHC) genotype, and although it is possible that only a single peptide epitope will relate to disease with multiple MHC genotypes, this controversy remains to be evaluated experimentally.
A recent report provided evidence that risk for islet autoimmunity dramatically increased in DR3/4-DQ8 siblings who shared both HLA haplotypes with their diabetic proband sibling (63% by age 7 and 85% by age 15) as compared with siblings who did not share both HLA haplotypes with their diabetic proband sibling (6) . These data suggest that HLA genotyping at birth may identify individuals at high risk of developing T1D before the occurrence of clear signs of islet autoimmunity.
The onset of T1D has been well characterized and occurs in a two-step manner of first asymptomatic inflammation of the pancreatic islets and second by a distinctive autoimmune process that leads to a decline in the pancreatic b-cell function and mass. Cells from both the innate and adaptive immune systems can be found within an insulitis lesion including T lymphocytes, B lymphocytes, macrophages (MF), and natural killer (NK) cells (7) (8) (9) (10) (11) . The autoimmune destruction of the pancreatic b cells takes place in a cell-mediated, organ-specific manner and requires both CD41 and CD81 T cells (8, 12, 13) as well as MF, which might be the first immune system cells present in the islets (12) (13) (14) (15) (16) (17) .
Activated MF present in the islets are able to secrete nitrogen and oxygen free radicals as well as various proinflammatory cytokines into their environment including: interleukin-1b (IL-1b), interleukin-12 (IL-12), interleukin-8, and tumor necrosis factor a (TNFa) (18) . Nitrogen and oxygen free radicals can directly penetrate cells causing intracellular damage to DNA, lipids, and proteins. The cytokines secreted from the activated MF can also invoke a response that initiates cellular damage in addition to free radical damage. Research has indicated that TNFa and IL-1b, produced by MF, along with interferon (IFN)g, produced by neighboring T cells, have a toxic effect on b cells (19) . It has also been demonstrated that a lack of IL-12, because of MF depletion experiments, actually prevents the differentiation of b-cell cytotoxic T cells in non-obese diabetic (NOD) mice (20) (21) (22) . Returning MF into the above-mentioned MF-depleted environment returns the ability of the immune system to generate active b-cell cytotoxic T cells in the NOD mouse (20) (21) (22) . These results indicate that cytokines not only can directly damage b cells but also can lead to indirect b-cell damage by activating other cell types.
Once the innate immune system has been activated within the pancreas, an adaptive immune response is subsequently triggered, generating autoreactive T cells, B cells, and antibodies. As T1D progresses in severity, so does the number of autoantigens targeted by T cells and autoantibodies being produced by B cells (23) . As pancreatic material is destroyed, T cells can be triggered to become autoreactive, wherein they present increased amounts of self-antigens from the damaged tissue. T cells that become autoreactive can activate B cells and signal generation of autoantibodies. This phenomena, known as epitope spreading, is illustrated once autoreactive T cells and B cells are fully capable of generating autoantibodies directed against numerous islet self-antigens including insulin, glutamic acid decarboxylase, 65-kDa isoform, islet cell antibody (ICA512)/islet antigen-2 (IA-2), and IA-2b (23) . Researchers are currently focusing on the study of the innate immune system to understand and determine its role in autoimmune disorders, such as T1D.
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Adaptive immune system
The immune system is comprised of two branches: the adaptive immune system and the innate immune system. The adaptive immune system functions to establish immunological memory and adapts to eliminate reoccurring pathogens more effectively and efficiently upon repeat exposure from a given pathogen. The adaptive immune system is an antigen-specific system that detects non-self molecules through the recognition of peptide antigens utilizing receptor interactions between T cells and antigen-presenting cells (APCs). Adaptive immunity establishes long-term immunological memory responses that trigger clonal expansion of T lymphocytes, which in turn work to signal B cells to produce antigen-specific antibodies (24) . T lymphocytes are somatically generated within the thymus, each with a structurally diverse and unique T cell receptor (TCR). The TCR functions to recognize processed peptides presented in the context of MHCs. Peptides presented through MHC Class-I structures interact with CD81 T cells, while those peptides presented through MHC Class-II structures interact with CD41 T cells. Once a processed peptide is recognized through a MHC-TCR interaction, a cascade of signaling events occurs, dependent upon the class of MHC structure recognized and the T cell type that is activated. Once activated, CD41 T cells promote T cell activation and differentiation, along with the ability to signal B cells to generate an antibody response. CD81 T cells when activated produce inflammatory mediators and can directly target the destruction of specific peptide-presenting cells.
The adaptive immune system has been well studied in the context of T1D development in both humans and the NOD mouse model system. Both T and B lymphocytes accumulate within the islet lesions, where they are triggered to initiate a full-blown immune response toward self-antigens. MF and monocytes first cause inflammation in the islets, followed by T and B cell infiltration. At this point, an individual still has the capability to synthesize insulin at a normal level. In an islet lesion, APCs present self-peptides to T cells. Once activated against self-peptides, T cells can go on to promote an autoimmune response and signal B cells to produce antibodies against selfantigens. During the development of diabetes, MHC Class-I restricted T cells are critical for disease pathogenesis in both humans and the NOD mouse (25, 26) . Autoreactive CD81 T cells appear to target self-antigens including insulin (27) and the isletspecific glucose 6-phosphatase catalytic subunitrelated protein (28) . Once cell types of the adaptive immune system become fully activated against selfantigens, the destruction of the b cells ultimately occurs. Although this process is well understood, attempts to control and prevent this destructive signal from occurring have failed to yield efficacious protection from disease onset.
Regulatory T cells
Regulatory T cells (T regs) are a specific population of T cells that are CD41 CD251 that generally express the forkhead transcription factor, forkhead box P3 (29) (30) (31) . T regs have been characterized because of their ability to suppress proliferation of effector T cells by shutting down interleukin-2 (IL-2) (32). Researchers have currently been focusing on the use of T regs in the prevention of T1D and other autoimmune diseases. Autoimmunity can develop because of a lack of T cell homeostasis, resulting from an inability to control or prevent chronic T cell activation from occurring. T regs possess the ability to control and prevent T cell activation and the signaling of chronic inflammatory responses (33, 34) . Unregulated effector T cells can become overactive and run the risk of becoming autoreactive if T regs are not able to regulate a proper immune response from occurring. Therefore, utilizing T regs to modulate effector T cells responses in an effort to prevent autoimmunity has become a strong area of research.
T regs are thought to control every aspect of autoimmune pathogenesis from expansion of T cell populations and T cell differentiation for influencing effector T cell function (35) . Although individuals with T1D have relatively equal numbers of T regs present compared with healthy controls (36-38), T regs isolated from patients with T1D displayed decreased suppressive activity in vitro, which suggests a defect in T reg function in individuals with T1D (36, 37) . Adoptive transfer experiments utilizing T regs in NOD mice show that T regs have the capability to cause distinct protective effects on T1D disease incidence and progression (39) . Adoptive transfer of T regs can be carried out with either a polyclonal T reg population or a more antigen-specific population of T regs. Experiments utilizing adoptive transfer of T regs into NOD mice illustrate that an islet antigen-specific population of T regs are 50 times more effective at preventing diabetes than a polyclonal population of T regs (35) . Researchers observed that effective prevention of diabetes onset is directly correlated with the ability of the T regs to become activated in the pancreatic lymph node (40) . T regs possess the ability to control immune responses in both the lympoid organs and the periphery at the site of an inflammatory response (35) . The possibility to utilize T regs therapeutically to prevent T1D in humans still needs more focused research, although preemptive trials utilizing adoptive transfer of T regs in graft-vs.-host disease therapy are currently taking place (35) .
Natural killer T cells
Natural killer T (NKT) cells are another subtype of T cells that has been identified as an important regulator of autoimmunity and T1D. NKT cells are a unique cell type that share common characteristics with both NK cells and T cells. NKT cells are capable of causing direct cell lysis because of Fas-ligand interactions along with the ability to induce cytotoxic effects on cells because of the production of IFNg (41) (42) (43) . A subset of NKT cells, which are biased toward TCR usage, recognize glycolipid antigens and express high levels of interleukin 4 (IL-4) (41) (42) (43) . Upon activation through a-galactosylceramide, a specific glycolipidligand, these TCR-biased NKT cells produce type 2 helper T cell response (Th2-type) responses mediated through IL-4 and interleukin-10, which inhibit type 1 helper T cell response (Th1) responses (44, 45) . NKT cells are numerically and functionally deficient in the thymus of diabetes-prone NOD mice (46, 47) . Humans suffering from T1D display a reduction in the frequency of total NKT cells along with a diminished capacity of NKT cells to secrete IL-4 (48). Adoptive transfer experiments utilizing NKT cells afford protection against the development of diabetes in NOD mice (49) . Thymus-derived NKT cells afford greater protection against T1D development than splenicderived NKT cells in NOD mice (50) . Continued research is necessary to fully determine how to utilize this unique subset of NKT cells to afford disease protection against T1D and autoimmunity in humans.
Innate immune system
The innate immune system functions as the first line of defense against microbes and infection. Unlike the adaptive immune system, the innate immune system does not generate long-term immunological memory. The innate immune system, once thought to be very non-specific, illustrates a much greater degree of specificity than previously thought (12) . This system employs multiple cell types including MF, dendritic cells (DCs), NK cells, neutrophils, and epithelial cells, each of which has its own specific function in an innate response from phagocytosis of infectious pathogens to direct targeted lysis of infected host cells.
In order to initiate an innate immune response, the host system first interacts with common surface molecules, expressed by an infectious organism. These common microbial surface molecules originally termed pathogen-associated molecular patterns (PAMPs) were predicted to interact with pattern recognition receptors (PRRs) found on the surface of cells. In contrast to adaptive immune system receptors, PRRs are not clonal receptors and lack the ability for clonal expansion (51) (52) (53) . The once hypothesized PRRs are now known to exist. One of the most commonly recognized groups of PRRs is the Toll-like receptors (TLRs) (51, 53, 54) .
TLRs
TLRs are an evolutionarily conserved class of receptors, consisting of 13 identified members in mammals (51, 53, 54) . TLRs share common structural features of a type I integral membrane glycoprotein, consisting of leucine-rich repeats in an extracellular domain and having a Toll/interleukin-1 receptor (IL-1R) (TIR) cytoplasmic domain (51, 53) . TLRs are PRRs and, as hypothesized, recognize many PAMPs including microbial membrane-derived molecules through TLR-2 and TLR-4, bacterial flagellin through TLR-5, as well as DNA and RNA from bacteria and viruses through TLRs 3, 7, 8, and 9 (51, 53, 54) . Although the majority of TLRs (TLRs 1, 2, 4 , 5, and 6) are found externally on the cell surface, some (TLRs 3, 7, 8, and 9) are found within the intracellular compartments (54) . TLRs also possess the ability to recognize a number of self-molecules expressed by the mammalian host (55), particularly molecules that are indicators of stress and disease (56) or molecules that are modified by a disease process. Oxidation (57) and the breakdown of extracellular matrix components (58) at the site of stress and inflammation are processes that convert self-molecules into ligands of TLRs.
Ligand binding to a specific TLR initiates a cascade of cell signaling and cellular activation. TLR signaling utilizes similar molecules to those used through IL-1R signaling (54) . Although each TLR has its own unique set of ligands, most TLRs utilize the adaptor protein myeloid differentiation factor 88 (MyD88) to internalize cell signaling; however, multiple internal activation pathways exist for TLRs (54) . TLR-activated cells respond by upregulating the production of numerous proinflammatory cytokines, chemokines, and costimulatory molecules to heighten innate immune cell sensitivity and to promote activation of the adaptive immune system (50, 51, (59) (60) (61) .
A general model of TLR signaling and activation is presented in Fig. 1 . TLRs (TLRs 1, 2, 4, 5, 6, 7, 8, 9, and 11) can promote cell activation through the MyD88-dependent pathway, but some of these TLRs can also carry out TLR activation in a MyD88-independent manner as well. TLRs and MyD88 association elicits the interleukin-1 receptor-associated kinase (IRAK) family. The IRAKs serve to activate tumor necrosis factor receptor-associated factor 6, which then signals activation of the transforming growth factor-b-protein kinase 1 (TAK1) complex. TAK1 ineracts with TAK1-binding proteins (TABs) to form the TAK1/TABs complex and when activated signals both the nuclear factor-kB (NF-kB) essential modulator (NEMO)/inhibitory kappa kinases (IKKs) complex and the mitogen-activated protein kinases TLR-3 activation occurs through the TIR domaincontaining adapter-inducing IFNb (Trif) pathway. Activated Trif signals through the tank-binding kinase-1 (TBK-1)/inducible IkB kinase (IKKi) complex. The TBK-1/IKKi complex mediates the phosphorylation of interferon regulatory factor-3 (IRF3), which then dimerizes. Free activated IRF3, AP-1, and NF-kB can translocate into the nucleus from the cytoplasm where they influence gene expression of various inflammatory cytokines and costimulatory molecules (61) . Figure 1 represents only a general view of TLR signaling pathways (61) .
Recent data implicate signal transduction through TLRs in the development of T1D in the NOD mouse. Knocking out expression of MyD88, the adapter protein responsible for most TLR signal transduction, protects NOD mice against the development of diabetes (62) . Loss of TLR-4 expression in the NOD mouse, however, leads to a higher incidence of diabetes compared with that of non-deficient TLR-4 littermates, whereas loss of TLRs 2, 3, or 9 has no effect on the development of diabetes (62) . Signaling through MyD88 appears to be important in T1D development, but the exact mechanistic details and specific TLR involvement remain to be elucidated.
Activation of the innate immune system acts as a prerequisite for the induction of an acquired immune response, particularly those of a T helper 1 cell response (52, 57, 58) . It has been suggested that TLRs are responsible for priming the adaptive immune system to become autoreactive toward self-antigens, thus ultimately controlling the progression of autoimmunity in diseases such as T1D, systemic lupus erythematosus (SLE), rheumatoid arthritis, Crohn's disease (63) , and heart failure (64). TLRs triggered through self-ligands could promote an unwarranted immune response, which in turn could non-specifically activate T cells because of cytokine and inflammatory signals.
Non-TLR PRRs
TLRs are one part of the innate immune system that has been extensively researched since their initial discovery in Drosophila in the late 1990s (51, 53) . Numerous non-TLR-associated innate immune receptors have recently been receiving attention including nod-like receptors (NLRs) (65) , triggering receptors expressed on myeloid cells (TREMs) (66) , and C-type lectin receptors (CLRs) (67); although these receptors have not been directly linked to T1D or autoimmunity, they represent a novel area for future exploration. TLRs are localized either at the cell surface or intracellular within compartments, such as endosomes (54) . NLRs are the cytoplasmic equivalent of TLRs (65) . NLRs are a family of PRRs capable of detecting pathogens within the cell cytosol (54, 65) . NLRs, although poorly understood, have been illustrated to induce inflammatory responses upon activation within the cytosol (65) . NLRs and TLRs work together to survey the entire cell against pathogens, but the exact details and specific signaling pathways are still unknown. TREMs function mainly as immune modulators, participating in numerous cell processes from regulating differentiation and function of MF and DCs for actively amplifying the effects of inflammation (66) . Defective TREMs have the potential to promote activation or amplify inflammation, leading to unnecessary innate and adaptive immune system activation. CLRs mediate host defense by binding PAMPs and function to activate and inhibit innate immune responses to pathogens or self (67) . Malfunctions in CLRs may promote inflammation because of a possible inability to properly signal the end of an innate immune response. The distinct relationship between non-TLR and TLR PRRs is not well understood, but the possibility of synergy or cross talk between these unique innate systems definitely possesses the potential to perpetuate and induce an adaptive immune response. Malfunctions in any of these innate systems or receptors, especially those responsible for amplifying or regulating an inflammatory response, could potentially trigger adverse and possibly detrimental immune responses, which may lead to a break in tolerance.
Innate influences over adaptive immunity
Although the innate and adaptive immune systems are discussed as two separate entities, both systems interact and communicate with one another. Each system has its own unique responsibilities that are beneficial for the health of the individual. The two immune systems communicate through physical cell surface recognition molecules and chemically through the release or uptake of various cytokines. Autoimmunity, uncontrolled inflammation, and chronic immune responses turn the most influential defense mechanism of the body into a ticking time bomb with the potential to cause serious damage. TLRs can recognize and bind both non-self and selfantigens (51, 53, 56, 58) . It has been proposed that PRRs that can interact with self-antigens have the ability to break central tolerance and signal an adaptive immune response, leading to the development of autoimmunity (64) . Ligand binding to a specific TLR initiates a specific cytokine production pattern. In general, TLR activation leads to the production of proinflammatory cytokines and mediators. In an unbalanced or compromised immune setting, an overt proinflammatory response may result in autoimmune diseases (68) .
Specific studies on Crohn's disease suggest that innate immune responses to bacterial flagella through TLR5-flagellin binding may actually promote an adjuvant-like effect on the adaptive immune system, thus prompting uncontrolled inflammatory responses in the adaptive immune system that promotes autoimmunity (63) . In SLE, TLR interactions with self-DNA, self-RNA, or self-nucleotide complexes through interactions with TLRs 3, 7, 8, and 9, all of which bind nucleotide molecules, have been proposed as an initiating trigger for the development of autoimmunity, termed the toll hypothesis (64) . Although the main function of PRRs is to bind bacterial and viral components, binding of self-nucleotide particles may lead to the stimulation of an innate immune response that elicits an autoimmune adaptive response, thus perpetuating the potential for the development of autoimmunity.
It is known that MF are the first cell type present within an islet lesion and are required for T1D disease progression (12) (13) (14) (15) (16) (17) . MF function mainly as phagocytic cells but also act as APCs, and once activated, produce multiple inflammatory cytokines and free radicals, capable of damaging b cells (13) . MF infiltrate first into a lesion, and then, an adaptive autoimmune response is triggered activating CD41 and CD81 T cells to become autoreactive (8, 12, 13) . MF have been thought to be the initiating cell type of T1D disease progression because of the protective nature on disease onset in MF depletion experiments and their ability to produce cytokines, which are responsible for the activation of both innate and adaptive immune responses (20) (21) (22) . Once activated, MF in an inflammatory lesion could easily target and present self-peptides to the incoming T cells. Once these T cells become autoreactive or effector in function, downregulating the immune response becomes difficult because of a lack of T reg function, previously mentioned in individuals predisposed and those suffering from T1D.
Several viruses have also been implicated as potential triggers of T1D including adenovirus, Coxsackie B virus, cytomegalovirus, hepatitis C virus, mumps virus, and rubella virus (69) (70) (71) (72) . As TLR-3 is known to recognize viral intermediate double-stranded RNA (dsRNA) and its mimic poly(I)poly(C) (51, 53, 54) , it has been receiving much attention as a possible link in the development of T1D and autoimmunity. TLR-3 activation leads to the production of IFNs, which serve to stimulate APCs and the adaptive immune system (61) . It has been demonstrated that bone marrow-derived MF from diabetic NOD mice express significantly higher basal levels of TLR-3 than that of prediabetic NOD mice and control strains (73) . Furthermore, stimulating these MF with poly(I)poly(C) elicits a nine-fold increase in production of type 1 IFNs in diabetic animals compared with non-diabetic controls (73) . It is not yet known what exact contribution this elevated TLR-3 expression has on T1D disease progression or onset, although one group has illustrated that TLR-3 expression in islets may be partially responsible for diabetes development in rat insulin promoter-B7.1 mice on a BALB/c genetic background when diabetes is precipitated with poly(I) poly(C) and insulin B9-23 peptide (74) .
A recent report indicated that loss of TLR-3 expression has no effect on the development of diabetes in the NOD mouse (62) . However, following viral infection, dsRNA intermediates or double-stranded DNA in the cytosol can trigger signal transduction leading to the production of type 1 IFNs by binding intracellular PRRs, retinoic-acid-inducible gene-1 (RIG-1), or melanoma-differentiation-associated gene-5 (MDA-5), thus bypassing TLR-3 (75) . Involvement of RIG-1 and MDA-5 in the context of diabetes development has not been assessed.
TLR activation could lead to chronic inflammatory responses, which may potentially steer the immune system down a path toward autoimmunity instead of host defense. Humans recently diagnosed with T1D display significantly higher levels of TNFa, IL-2, and other proinflammatory cytokines in their peripheral blood (76) . It has also been shown that the presence of high blood glucose concentrations has the ability to induce the expression of proinflammatory molecules in monocytes (77) . In a system where it is key to control T cell activation, excessive IL-2 along with the induction and production of proinflammatory cytokines makes T cell homeostatic control even more difficult for patients with T1D.
Studies utilizing NOD mice have revealed that newonset diabetic NOD mice have the potential to generate bone marrow-derived MF, which exhibit altered basal expression patterns of TLRs, that is, Th1 biased and upon activation produces heightened cytokine production compared with normal mice (73) . These bone marrow-derived MF have increased TLR expression, TLR signaling responses, and heightened cytokine expression and production (73) . Although these MF are generated in vitro, it is likely that the precursor cells in vivo may give rise to tissue MF with similar altered characteristics. Hypersensitive proinflammatory MF may promote a chronic inflammatory state, which could induce uncontrolled T cell activation and shift the immune system toward autoimmune responses.
Even though TLRs are thought of as being solely involved in the innate immune system, research has indicated that TLRs are expressed in cells of the adaptive immune system as well (78) . TLRs are expressed by T cells and possess the ability to modify T cell activities (78) . T cells from human peripheral blood samples show expression of TLRs 1, 2, 3, 4, 5, 7, and 9, although individual expression levels for each TLR vary (79) (80) (81) . TLR expression is regulated through concomitant TCR-dependent stimulation, but costimulation of TLRs and the TCR can influence T cell function and proliferation (78) . Although this topic is relatively new, certain TLRs (TLRs 2, 3, 5, and 9) have been categorized as being able to modify and enhance T cell proliferation and cytokine production of TCR-stimulated T cells (78) . Additional studies on T regs have illustrated that activation of TLRs 2, 5, and/or 8 has the ability to suppress T reg activity (78) .
One could hypothesize a bacterial infection that elicits TLR-2 and TLR-4 activation. TLR activation may lead to the enhancement of effecter T cells not only from cytokine signals produced through cells of the innate immune system but also from direct TLR-2 recognition by T cells themselves. Diabetic individuals or those progressing toward T1D may have T regs that lack proper homeostatic function. Add to this bone marrow precursor cells that when differentiated generate proinflammatory cell types and you have an immune system that is primed to generate inflammatory responses with an inability to stop or regulate them. This type of system could easily steer unregulated, chronically activated cell types toward autoimmunity. More in-depth research into this topic needs to be generated, but one could envision how an inflammatory biased system could be triggered upon a simple bacterial infection.
Conclusion
The immune system as a whole has developed to prevent damage and sustain the health of the host. The once overshadowed innate immune system has a vital role in host defense and the signaling of an adaptive immune response. Malfunctions in either immune system have the potential to lead to autoimmune complications, but recently, the roles of the innate immune system in perpetuating autoimmunity has become an interesting area of research focus, especially in T1D. The innate system primes the entire immune system to signal a full-blown adaptive immune response in the face of an infection. T1D is an autoimmune disease that requires cell types from both the innate and adaptive immune system for disease progression. Although the exact trigger to initiate the adaptive immune response responsible for signaling the destruction of the b cells in the pancreas is not fully understood, looking toward malfunctions and or signaling through the innate system is necessary to fully understand the development of autoimmunity in T1D. Effectively manipulating TLR signaling may help to elucidate the underlying mechanisms of T1D development. Discovering novel potential candidate receptors or molecules capable of affording protection against T1D is necessary in order to design therapeutic strategies in an effort to find a cure for T1D.
